GT Biopharma (FRA:OXIA) Cyclically Adjusted Book per Share: €-11,098.75 (As of Mar. 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Cyclically Adjusted Book per Share?

GT Biopharma FRA:OXIA 21 Cyclically Adjusted Book per Share is €-11,098.75 as of Mar. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

GT Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was €0.186. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-11,098.75 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -2.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -58.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of GT Biopharma was 4.00% per year. The lowest was -717.40% per year. And the median was -5.50% per year.

As of today (2026-07-05), GT Biopharma's current stock price is €4.77. GT Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-11,098.75. GT Biopharma's Cyclically Adjusted PB Ratio of today is .


GT Biopharma  (FRA:OXIA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


GT Biopharma Cyclically Adjusted Book per Share Related Terms


GT Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Cyclically Adjusted Book per Share Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -725.13 -866.51 -777.54 -1,422.91 -5,662.58

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,043.89 -1,237.64 -7,604.19 -5,662.58 -11,098.75

FRA:OXIA vs INTI, HIND, TPST: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, GT Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cyclically Adjusted PB Ratio falls into.


FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GT Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.186/330.2130*330.2130
=0.186

Current CPI (Mar. 2026) = 330.2130.

GT Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 -5.611 241.018 -7.687
201609 -6.110 241.428 -8.357
201612 -7.156 241.432 -9.787
201703 -16,778.000 243.801 -22,724.737
201706 -17,727.000 244.955 -23,896.985
201709 2,173.561 246.819 2,907.953
201712 2,171.612 246.524 2,908.822
201803 2,088.929 249.554 2,764.097
201806 2,150.735 251.989 2,818.380
201809 117.878 252.439 154.195
201812 102.434 251.233 134.636
201903 89.228 254.202 115.909
201906 78.544 256.143 101.257
201909 -125.595 256.759 -161.525
201912 -125.766 256.974 -161.610
202003 -135.681 258.115 -173.580
202006 -164.128 257.797 -210.232
202009 -165.513 260.280 -209.984
202012 -139.057 260.474 -176.288
202103 29.700 264.877 37.026
202106 32.261 271.696 39.209
202109 26.782 274.310 32.240
202112 18.138 278.802 21.483
202203 14.982 287.504 17.208
202206 14.277 296.311 15.910
202209 14.864 296.808 16.537
202212 10.152 296.797 11.295
202303 9.919 301.836 10.852
202306 8.012 305.109 8.671
202309 6.788 307.789 7.283
202312 4.963 306.746 5.343
202403 3.538 312.332 3.741
202406 2.290 314.175 2.407
202409 0.845 315.301 0.885
202412 -0.714 315.605 -0.747
202503 -0.358 319.799 -0.370
202506 0.757 322.561 0.775
202509 0.422 324.800 0.429
202512 0.194 324.054 0.198
202603 0.186 330.213 0.186

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-11,098.75 mean?
GT Biopharma (FRA:OXIA) has a Cyclically Adjusted Book per Share of €-11,098.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Cyclically Adjusted Book per Share too high?
GT Biopharma's current Cyclically Adjusted Book per Share is €-11,098.75. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Cyclically Adjusted Book per Share compare to INTI and HIND?
GT Biopharma's Cyclically Adjusted Book per Share of €-11,098.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GT Biopharma and its competitors. GT Biopharma's current Cyclically Adjusted Book per Share is €-11,098.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Cyclically Adjusted Book per Share of €-11,098.75. The current Cyclically Adjusted Book per Share is €-11,098.75. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Cyclically Adjusted Book per Share is €-11,098.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price